Logo image of MEDP

MEDPACE HOLDINGS INC (MEDP) Stock Fundamental Analysis

NASDAQ:MEDP - Nasdaq - US58506Q1094 - Common Stock - Currency: USD

321.93  -1.57 (-0.49%)

Fundamental Rating

7

Taking everything into account, MEDP scores 7 out of 10 in our fundamental rating. MEDP was compared to 56 industry peers in the Life Sciences Tools & Services industry. MEDP has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. MEDP has a decent growth rate and is not valued too expensively. With these ratings, MEDP could be worth investigating further for quality investing!.


Dividend Valuation Growth Profitability Health

Quickly go to:

9

1. Profitability

1.1 Basic Checks

MEDP had positive earnings in the past year.
In the past year MEDP had a positive cash flow from operations.
In the past 5 years MEDP has always been profitable.
MEDP had a positive operating cash flow in each of the past 5 years.
MEDP Yearly Net Income VS EBIT VS OCF VS FCFMEDP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

1.2 Ratios

The Return On Assets of MEDP (21.95%) is better than 98.21% of its industry peers.
MEDP's Return On Equity of 70.14% is amongst the best of the industry. MEDP outperforms 98.21% of its industry peers.
Looking at the Return On Invested Capital, with a value of 49.81%, MEDP belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for MEDP is significantly above the industry average of 13.15%.
The 3 year average ROIC (38.75%) for MEDP is below the current ROIC(49.81%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 21.95%
ROE 70.14%
ROIC 49.81%
ROA(3y)18.14%
ROA(5y)15.16%
ROE(3y)54.33%
ROE(5y)40%
ROIC(3y)38.75%
ROIC(5y)29.27%
MEDP Yearly ROA, ROE, ROICMEDP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60

1.3 Margins

MEDP has a better Profit Margin (19.31%) than 96.43% of its industry peers.
In the last couple of years the Profit Margin of MEDP has grown nicely.
MEDP's Operating Margin of 21.16% is amongst the best of the industry. MEDP outperforms 89.29% of its industry peers.
MEDP's Operating Margin has improved in the last couple of years.
Looking at the Gross Margin, with a value of 31.51%, MEDP is doing worse than 73.21% of the companies in the same industry.
In the last couple of years the Gross Margin of MEDP has grown nicely.
Industry RankSector Rank
OM 21.16%
PM (TTM) 19.31%
GM 31.51%
OM growth 3Y6.82%
OM growth 5Y7.46%
PM growth 3Y6.48%
PM growth 5Y10.5%
GM growth 3Y2.7%
GM growth 5Y1.75%
MEDP Yearly Profit, Operating, Gross MarginsMEDP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 20 30 40

More info and screens

8

2. Health

2.1 Basic Checks

MEDP has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
MEDP has less shares outstanding than it did 1 year ago.
MEDP has less shares outstanding than it did 5 years ago.
There is no outstanding debt for MEDP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
MEDP Yearly Shares OutstandingMEDP Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
MEDP Yearly Total Debt VS Total AssetsMEDP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

2.2 Solvency

MEDP has an Altman-Z score of 5.82. This indicates that MEDP is financially healthy and has little risk of bankruptcy at the moment.
MEDP has a better Altman-Z score (5.82) than 87.50% of its industry peers.
MEDP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 5.82
ROIC/WACC4.72
WACC10.56%
MEDP Yearly LT Debt VS Equity VS FCFMEDP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.3 Liquidity

A Current Ratio of 0.73 indicates that MEDP may have some problems paying its short term obligations.
With a Current ratio value of 0.73, MEDP is not doing good in the industry: 92.86% of the companies in the same industry are doing better.
MEDP has a Quick Ratio of 0.73. This is a bad value and indicates that MEDP is not financially healthy enough and could expect problems in meeting its short term obligations.
MEDP has a worse Quick ratio (0.73) than 87.50% of its industry peers.
The current and quick ratio evaluation for MEDP is rather negative, while it does have excellent solvency and profitability. These ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
Industry RankSector Rank
Current Ratio 0.73
Quick Ratio 0.73
MEDP Yearly Current Assets VS Current LiabilitesMEDP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 33.54% over the past year.
The Earnings Per Share has been growing by 33.22% on average over the past years. This is a very strong growth
Looking at the last year, MEDP shows a quite strong growth in Revenue. The Revenue has grown by 9.87% in the last year.
Measured over the past years, MEDP shows a quite strong growth in Revenue. The Revenue has been growing by 19.62% on average per year.
EPS 1Y (TTM)33.54%
EPS 3Y37.96%
EPS 5Y33.22%
EPS Q2Q%14.69%
Revenue 1Y (TTM)9.87%
Revenue growth 3Y22.68%
Revenue growth 5Y19.62%
Sales Q2Q%9.3%

3.2 Future

The Earnings Per Share is expected to grow by 8.31% on average over the next years. This is quite good.
The Revenue is expected to grow by 6.53% on average over the next years.
EPS Next Y2.91%
EPS Next 2Y3.1%
EPS Next 3Y5.56%
EPS Next 5Y8.31%
Revenue Next Year3.72%
Revenue Next 2Y3.54%
Revenue Next 3Y5.16%
Revenue Next 5Y6.53%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
MEDP Yearly Revenue VS EstimatesMEDP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 1B 2B 3B
MEDP Yearly EPS VS EstimatesMEDP Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 5 10 15 20 25

More info and screens

5

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 24.57, MEDP is valued on the expensive side.
73.21% of the companies in the same industry are more expensive than MEDP, based on the Price/Earnings ratio.
When comparing the Price/Earnings ratio of MEDP to the average of the S&P500 Index (27.41), we can say MEDP is valued inline with the index average.
The Price/Forward Earnings ratio is 23.98, which indicates a rather expensive current valuation of MEDP.
75.00% of the companies in the same industry are more expensive than MEDP, based on the Price/Forward Earnings ratio.
The average S&P500 Price/Forward Earnings ratio is at 35.19. MEDP is valued slightly cheaper when compared to this.
Industry RankSector Rank
PE 24.57
Fwd PE 23.98
MEDP Price Earnings VS Forward Price EarningsMEDP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, MEDP is valued a bit cheaper than 78.57% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of MEDP indicates a rather cheap valuation: MEDP is cheaper than 87.50% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 17.1
EV/EBITDA 18.24
MEDP Per share dataMEDP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 40 60

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
MEDP has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)8.46
PEG (5Y)0.74
EPS Next 2Y3.1%
EPS Next 3Y5.56%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for MEDP!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MEDPACE HOLDINGS INC

NASDAQ:MEDP (7/14/2025, 12:24:53 PM)

321.93

-1.57 (-0.49%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)04-21 2025-04-21/amc
Earnings (Next)07-21 2025-07-21/amc
Inst Owners89.98%
Inst Owner Change-0.04%
Ins Owners0.54%
Ins Owner Change5.95%
Market Cap9.25B
Analysts70
Price Target306.75 (-4.72%)
Short Float %13.56%
Short Ratio6.72
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)19.73%
Min EPS beat(2)17.84%
Max EPS beat(2)21.62%
EPS beat(4)4
Avg EPS beat(4)12.98%
Min EPS beat(4)6.19%
Max EPS beat(4)21.62%
EPS beat(8)7
Avg EPS beat(8)11.62%
EPS beat(12)11
Avg EPS beat(12)14.86%
EPS beat(16)15
Avg EPS beat(16)14.75%
Revenue beat(2)1
Avg Revenue beat(2)1.21%
Min Revenue beat(2)-1.63%
Max Revenue beat(2)4.04%
Revenue beat(4)1
Avg Revenue beat(4)-0.75%
Min Revenue beat(4)-3.35%
Max Revenue beat(4)4.04%
Revenue beat(8)3
Avg Revenue beat(8)-0.2%
Revenue beat(12)7
Avg Revenue beat(12)0.82%
Revenue beat(16)8
Avg Revenue beat(16)0.41%
PT rev (1m)0%
PT rev (3m)-13.19%
EPS NQ rev (1m)-0.34%
EPS NQ rev (3m)-1.68%
EPS NY rev (1m)0.42%
EPS NY rev (3m)3.32%
Revenue NQ rev (1m)0.05%
Revenue NQ rev (3m)1.13%
Revenue NY rev (1m)0.09%
Revenue NY rev (3m)1.6%
Valuation
Industry RankSector Rank
PE 24.57
Fwd PE 23.98
P/S 4.29
P/FCF 17.1
P/OCF 15.9
P/B 15.59
P/tB N/A
EV/EBITDA 18.24
EPS(TTM)13.1
EY4.07%
EPS(NY)13.43
Fwd EY4.17%
FCF(TTM)18.82
FCFY5.85%
OCF(TTM)20.25
OCFY6.29%
SpS75.04
BVpS20.65
TBVpS-3.58
PEG (NY)8.46
PEG (5Y)0.74
Profitability
Industry RankSector Rank
ROA 21.95%
ROE 70.14%
ROCE 58.88%
ROIC 49.81%
ROICexc 115.73%
ROICexgc N/A
OM 21.16%
PM (TTM) 19.31%
GM 31.51%
FCFM 25.08%
ROA(3y)18.14%
ROA(5y)15.16%
ROE(3y)54.33%
ROE(5y)40%
ROIC(3y)38.75%
ROIC(5y)29.27%
ROICexc(3y)71.87%
ROICexc(5y)52.56%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)47.22%
ROCE(5y)35.45%
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3Y64.05%
ROICexc growth 5Y48.31%
OM growth 3Y6.82%
OM growth 5Y7.46%
PM growth 3Y6.48%
PM growth 5Y10.5%
GM growth 3Y2.7%
GM growth 5Y1.75%
F-Score8
Asset Turnover1.14
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 140.62%
Cap/Sales 1.9%
Interest Coverage 250
Cash Conversion 119.87%
Profit Quality 129.91%
Current Ratio 0.73
Quick Ratio 0.73
Altman-Z 5.82
F-Score8
WACC10.56%
ROIC/WACC4.72
Cap/Depr(3y)142.96%
Cap/Depr(5y)144.54%
Cap/Sales(3y)2.07%
Cap/Sales(5y)2.41%
Profit Quality(3y)141.71%
Profit Quality(5y)142.32%
High Growth Momentum
Growth
EPS 1Y (TTM)33.54%
EPS 3Y37.96%
EPS 5Y33.22%
EPS Q2Q%14.69%
EPS Next Y2.91%
EPS Next 2Y3.1%
EPS Next 3Y5.56%
EPS Next 5Y8.31%
Revenue 1Y (TTM)9.87%
Revenue growth 3Y22.68%
Revenue growth 5Y19.62%
Sales Q2Q%9.3%
Revenue Next Year3.72%
Revenue Next 2Y3.54%
Revenue Next 3Y5.16%
Revenue Next 5Y6.53%
EBIT growth 1Y28.65%
EBIT growth 3Y31.04%
EBIT growth 5Y28.55%
EBIT Next Year10.29%
EBIT Next 3Y8.11%
EBIT Next 5Y9.37%
FCF growth 1Y40.57%
FCF growth 3Y34.54%
FCF growth 5Y25.47%
OCF growth 1Y37.94%
OCF growth 3Y32.23%
OCF growth 5Y24.7%